Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will

This article was originally published in Start Up

Executive Summary

Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.

You may also be interested in...



Kleiner Perkins Prepares for Biotech's New Golden Age

Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.

Kleiner Perkins Prepares for Biotech's New Golden Age

Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.

Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets

In 2003, the combined US potential market for tissue-engineering products totaled approximately $58.1 billion. By 2013, the potential market is expected to increase at a compound rate of 4.8%, reaching $92.8 billion, with a number of segments growing at an even faster rate than the market overall.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC091076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel